Pharmaceutical Research & Drug Development – Page 4

Species selection questioned during program hold risk review – preventing clinical hold

Addressing Species Selection Issues During Program Hold Risk Review During the drug development process, particularly in preclinical studies, questions about species selection can lead to significant program holds. These holds…

Non-clinical toxicity findings during study audit – CAPA for study design gaps

Recognizing early indicators of non-clinical toxicity is essential to mitigating risks. Symptoms can manifest in various forms, and it is critical to capture them accurately to facilitate a focused investigation.…

GLP readiness concerns during program hold risk review – how to defend preclinical package

Recognizing symptoms or signals is the first step in addressing GLP readiness concerns effectively. These can manifest in various ways, affecting both laboratory operations and program timelines. Key indicators include:Click…

Study design not regulator-aligned during sponsor oversight – CAPA for study design gaps

In the context of pharmaceutical development, symptoms indicating potential study design misalignments may be subtle but can significantly impact outcomes. These symptoms may present in various forms:Click to read the…

Study design not regulator-aligned during sponsor oversight – preventing clinical hold

Identifying symptoms or signals early in the clinical trial process can dramatically reduce the risk of regulatory misalignment. Below are common indicators of potential study design issues:Click to read the…

Non-clinical toxicity findings during study audit – how to defend preclinical package

The first step in addressing non-clinical toxicity findings is identifying the symptoms or signals within the laboratory or clinical environment. Typical symptoms might include increased mortality rates in test subjects,…

Species selection questioned during regulatory submission prep – FDA/EMA non-clinical expectations

Identifying symptoms early can significantly improve the response to species selection challenges. Symptoms may manifest in several ways, including:Click to read the full article.

Species selection questioned during IND-enabling studies – FDA/EMA non-clinical expectations

Investigating Species Selection Concerns in IND-Enabling Studies for Regulatory Compliance In the intricate landscape of drug development, the species selection in IND-enabling studies has become a focal point for scrutiny.…

Dose justification weak during regulatory submission prep – FDA/EMA non-clinical expectations

Identifying weak dose justification starts with recognizing specific symptoms or signals that suggest potential deficiencies in preclinical studies. Some common indicators include:Click to read the full article.

Study design not regulator-aligned during study audit – FDA/EMA non-clinical expectations

Identifying symptoms of misalignment begins with observing signals on the laboratory floor or during study audits. Common signals include:Click to read the full article.

GLP readiness concerns during study audit – how to defend preclinical package

An effective investigation begins with recognizing the symptoms of GLP readiness concerns. During a study audit, several symptoms may surface, signaling potential compliance issues:Click to read the full article.

Reproducibility gaps during study audit – preventing clinical hold

The initial identification of reproducibility gaps often arises from a range of subtle and overt signals during study audits or routine laboratory evaluations. These symptoms may include:Click to read the…